AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,614 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,228 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,614every one kept
Companies4,788with at least one brief
Recent filings2,228filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
- Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
- Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
- Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
- Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Read the filing on SEC.gov ↗
Douglas Elliman reported third-quarter 2026 net income of $7.4 million, or $0.08 per diluted share, compared with a net loss of $24.7 million a year earlier, while revenue fell to $252.1 million from $262.8 million. Adjusted EBITDA was a $5.3 million loss versus $1.0 million of income, and the company also approved a $10 million share repurchase program, which it says will be funded from cash on hand.
- Q3 2026 revenue was $252.1 million vs. $262.8 million in Q3 2025; the company sold its property management business in October 2025.
- Q3 operating income was $6.3 million vs. an operating loss of $10.7 million; Adjusted EBITDA was a $5.3 million loss vs. $1.0 million of income.
- Nine-month revenue was $749.9 million vs. $787.6 million, and the net loss narrowed to $11.6 million ($0.14 per share) from $53.3 million ($0.63 per share).
- The Board approved a $10 million share repurchase program; cash and a Treasury bill totaled about $123 million with no long-term debt as of September 30, 2026.
Read the filing on SEC.gov ↗
Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.
- Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
- Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
- Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
- In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.
Read the filing on SEC.gov ↗
Bain Capital Specialty Finance (BCSF) reported third-quarter 2026 net investment income of $27.7 million, or $0.43 per share, down from $28.6 million, or $0.44 per share, in the second quarter. Net increase in net assets from operations rose to $0.26 per share from $0.22, while net asset value per share fell to $16.49 from $16.65. The company also declared a fourth-quarter dividend of $0.42 per share and appointed Amrit Kanwal as an independent director, expanding the board to nine members.
- Q3 2026 net investment income was $27.7 million, or $0.43 per share, versus $28.6 million, or $0.44 per share, in Q2 2026; total investment income was $59.9 million, versus $62.3 million.
- Net increase in net assets from operations was $16.7 million, or $0.26 per share, versus $0.22 per share in Q2 2026; net asset value per share was $16.49 at September 30, 2026, versus $16.65 at June 30, 2026.
- Board declared a fourth-quarter 2026 dividend of $0.42 per share, with a record date of December 15, 2026 and payment on or before December 29, 2026.
- Amrit Kanwal, 61, was appointed an independent Class III director effective November 4, 2026, and joined the Audit, Nominating and Corporate Governance, and Compensation Committees.
Read the filing on SEC.gov ↗
Nine Energy Service reported third quarter 2026 revenue of $142.0 million, essentially unchanged from the second quarter's $141.8 million. Net loss widened to $5.1 million, or $(0.36) per share, from $4.9 million, or $(0.35) per share, and adjusted EBITDA fell to $8.3 million from $8.6 million. For shareholders, the company expects fourth quarter revenue to be flat and profitability to be modestly higher than the third quarter.
- Q3 2026 revenue of $142.0 million versus $141.8 million in Q2 2026; cementing revenue rose 11% quarter over quarter.
- Net loss of $5.1 million ($0.36 per share) in Q3 2026 versus $4.9 million ($0.35 per share) in Q2 2026.
- Adjusted EBITDA of $8.3 million in Q3 2026 versus $8.6 million in Q2 2026.
- Management expects Q4 2026 revenue to be flat and profitability to be modestly higher than Q3; total liquidity was $46.0 million at September 30, 2026.
Read the filing on SEC.gov ↗
Exodus Movement reported third quarter 2026 revenue of $32.5 million, up 7% from $30.3 million a year earlier, but swung to a net loss of $8.3 million attributable to the company from net income of $17.0 million in the prior-year quarter. General and administrative expenses rose 94% to $28.9 million, and the company said it expects to cut combined annual costs by about $30 million going into 2027 following the Monavate and Baanx acquisitions.
- Q3 2026 revenue was $32.5 million, up 7% from $30.3 million in Q3 2025
- Net loss attributable to Exodus was $8.3 million, versus net income of $17.0 million a year earlier
- Adjusted EBITDA was a loss of $3.9 million, compared with positive $5.9 million in Q3 2025
- Exodus is on track to reduce combined annual costs by about $30 million going into 2027
Read the filing on SEC.gov ↗
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
- Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
- GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
- Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
- For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Read the filing on SEC.gov ↗
Bakkt reported third-quarter 2026 revenue of $149.2 million, down 62.9% from $402.2 million a year earlier, mainly due to lower crypto trading volume and the loss of clients. The company posted net income of $14.3 million, or $0.31 per diluted share, versus a net loss of $14.9 million in Q3 2025, and the filing notes the result includes a $26.8 million non-cash gain on the Transchem warrants. It reiterated a full-year 2026 Total Transacting Volume target of approximately $3 billion and set a first-half 2027 target of approximately $6 billion.
- Q3 2026 total revenue was $149.2 million versus $402.2 million in Q3 2025; net income attributable to Bakkt was $14.3 million, or $0.31 per diluted share
- Adjusted EBITDA loss narrowed to $11.8 million from $14.8 million in Q3 2025 on a consistent basis
- TTV was $147.9 million for Q3 2026; the company reiterated its approximately $3 billion full-year 2026 target and set an approximately $6 billion first-half 2027 target
- Cash, cash equivalents and restricted cash were $37.3 million as of September 30, 2026, versus $50.7 million as of June 30, 2026
Read the filing on SEC.gov ↗
Ranger Energy Services reported third quarter 2026 revenue of $162.8 million, up from $128.9 million a year earlier but down from $176.5 million in the second quarter, with net income of $2.5 million or $0.10 per diluted share. The company also declared a quarterly dividend of $0.06 per share, payable December 4, 2026, which signals continued cash returns to shareholders.
- Q3 2026 revenue was $162.8 million, versus $176.5 million in Q2 2026 and $128.9 million in Q3 2025
- Net income was $2.5 million, or $0.10 per diluted share, versus $0.29 per diluted share in Q2 2026 and $0.05 in Q3 2025
- Adjusted EBITDA was $20.1 million, down from $28.6 million in Q2 2026 but up from $16.8 million in Q3 2025
- Quarterly dividend of $0.06 per share payable December 4, 2026, to holders of record on November 20, 2026
Read the filing on SEC.gov ↗
Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per share, up from $26.0 million, or $0.35 per share, a year earlier, as research and development spending rose. Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, which the company says should fund planned clinical milestones and operations into 2028.
- Q3 2026 net loss was $32.4 million ($0.27 per share), versus $26.0 million ($0.35 per share) in Q3 2025; weighted average shares rose to 120.7 million from 74.3 million.
- Research and development expenses were $26.1 million, up from $20.3 million; general and administrative expenses were $8.3 million, up from $7.7 million.
- Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, versus about $145 million at December 31, 2025.
- On October 2026, the FDA granted Fast Track Designation to PSV359 for FAP-positive solitary fibrous tumors.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.